Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Colorcon
Boehringer Ingelheim
Johnson and Johnson
McKinsey

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR KEVZARA

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for KEVZARA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03414502 ↗ Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response Recruiting University of Nebraska Phase 3 2007-08-01 This is a 16-week, open-label study to identify factors that help predict clinical responses to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is determined to be necessary will be considered end of study. End of study data (week 16) as well as study serum will be collected. (Serum only collected on those subjects who have consented to the addendum Serum and DNA of this study). A portion of the blood collected at baseline, week 8 and week 16 with the addendum portion of the study is for future research and will be utilized attempting to look to detect the generation of superoxide radicals. The radicals have been shown to be associated with inflammation and may correlate with the progression of RA. If this is true, then treatment with RA should decrease the levels of these radicals signaling response to treatment.
NCT03600818 ↗ Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Terminated Regeneron Pharmaceuticals Phase 3 2018-10-09 Primary Objective: To evaluate the efficacy of KEVZARA (sarilumab) in patients with polymyalgia rheumatica (PMR) as assessed by the proportion of subjects with sustained remission for sarilumab with a shorter corticosteroid (CS) tapering regimen as compared to placebo with a longer CS tapering regimen. Secondary Objectives: - To demonstrate the efficacy of sarilumab in patients with polymyalgia rheumatica compared to placebo, in combination with a CS taper with regards to: - Clinical responses (such as components of sustained remission, disease remission rates, time to first disease flare) over time. - Cumulative CS (including prednisone) exposure. - To assess the safety (including immunogenicity) and tolerability of sarilumab in patients with PMR. - To measure sarilumab serum concentrations in patients with PMR. - To assess the effect of sarilumab in reducing glucocorticoid toxicity as measured by the composite glucocorticoid toxicity index (GTI) questionnaire.
NCT03600818 ↗ Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Terminated Sanofi Phase 3 2018-10-09 Primary Objective: To evaluate the efficacy of KEVZARA (sarilumab) in patients with polymyalgia rheumatica (PMR) as assessed by the proportion of subjects with sustained remission for sarilumab with a shorter corticosteroid (CS) tapering regimen as compared to placebo with a longer CS tapering regimen. Secondary Objectives: - To demonstrate the efficacy of sarilumab in patients with polymyalgia rheumatica compared to placebo, in combination with a CS taper with regards to: - Clinical responses (such as components of sustained remission, disease remission rates, time to first disease flare) over time. - Cumulative CS (including prednisone) exposure. - To assess the safety (including immunogenicity) and tolerability of sarilumab in patients with PMR. - To measure sarilumab serum concentrations in patients with PMR. - To assess the effect of sarilumab in reducing glucocorticoid toxicity as measured by the composite glucocorticoid toxicity index (GTI) questionnaire.
NCT03679845 ↗ Study to Assess Sarilumab in Halting Progression of Morphea Withdrawn Regeneron Pharmaceuticals Phase 1/Phase 2 2019-09-01 An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.
NCT03679845 ↗ Study to Assess Sarilumab in Halting Progression of Morphea Withdrawn Massachusetts General Hospital Phase 1/Phase 2 2019-09-01 An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for KEVZARA

Condition Name

Condition Name for KEVZARA
Intervention Trials
Cytokine Storm 1
Interaction 1
Morphea, Plaque Form 1
Polymyalgia Rheumatica 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for KEVZARA
Intervention Trials
Arthritis, Rheumatoid 2
Arthritis 2
COVID-19 2
Virus Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for KEVZARA

Trials by Country

Trials by Country for KEVZARA
Location Trials
United States 12
Spain 2
Denmark 2
Belgium 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for KEVZARA
Location Trials
Massachusetts 2
Washington 1
Texas 1
Pennsylvania 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for KEVZARA

Clinical Trial Phase

Clinical Trial Phase for KEVZARA
Clinical Trial Phase Trials
Phase 3 2
Phase 2 3
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for KEVZARA
Clinical Trial Phase Trials
Recruiting 2
Terminated 2
Completed 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for KEVZARA

Sponsor Name

Sponsor Name for KEVZARA
Sponsor Trials
Regeneron Pharmaceuticals 2
Sanofi 1
University of Southern Denmark 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for KEVZARA
Sponsor Trials
Other 14
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
Dow
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.